David M. Reese's most recent trade in AMGEN Inc. was a trade of 556 Common Stock done at an average price of $331.1 . Disclosure was reported to the exchange on May 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 331.11 per share. | 07 May 2026 | 556 | 42,256 (0%) | 0% | 331.1 | 184,097 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2026 | 19,002 | 19,002 | - | - | Nqso (Right to Buy) | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2026 | 2,912 | 43,266 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 329.59 per share. | 05 May 2026 | 454 | 42,812 (0%) | 0% | 329.6 | 149,634 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 329.82 per share. | 02 May 2026 | 746 | 41,041 (0%) | 0% | 329.8 | 246,046 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 329.82 per share. | 02 May 2026 | 687 | 40,354 (0%) | 0% | 329.8 | 226,586 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 366.21 per share. | 16 Mar 2026 | 6,022 | 41,787 (0%) | 0% | 366.2 | 2,205,317 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2025 | 6,490 | 35,812 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2025 | 309 | 35,503 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 22,944 | 22,944 | - | - | Nqso (Right to Buy) | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 3,549 | 42,116 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.78 per share. | 02 May 2025 | 702 | 39,232 (0%) | 0% | 283.8 | 199,214 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.78 per share. | 02 May 2025 | 665 | 38,567 (0%) | 0% | 283.8 | 188,714 | Common Stock |
| Amgen | Reese David M. | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 288.56 per share. | 30 Apr 2025 | 768 | 39,934 (0%) | 0% | 288.6 | 221,614 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 313.71 per share. | 17 Mar 2025 | 3,635 | 40,702 (0%) | 0% | 313.7 | 1,140,336 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 7,277 | 44,199 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 304.44 per share. | 19 Feb 2025 | 25,225 | 36,922 (0%) | 0% | 304.4 | 7,679,524 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 8,711 | 0 | - | - | Nqso (Right to Buy) | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 156.35 per share. | 19 Feb 2025 | 8,711 | 70,858 (0%) | 0% | 156.4 | 1,361,965 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 293.22 per share. | 19 Feb 2025 | 8,711 | 62,147 (0%) | 0% | 293.2 | 2,554,224 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 20,767 | 20,767 | - | - | Nqso (Right to Buy) | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 3,196 | 61,889 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 311.29 per share. | 05 May 2024 | 633 | 58,693 (0%) | 0% | 311.3 | 197,047 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 277.37 per share. | 02 May 2024 | 650 | 59,326 (0%) | 0% | 277.4 | 180,291 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 276.38 per share. | 30 Apr 2024 | 690 | 59,976 (0%) | 0% | 276.4 | 190,702 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 268.87 per share. | 18 Mar 2024 | 6,202 | 60,666 (0%) | 0% | 268.9 | 1,667,532 | Common Stock |
| Amgen | David M. Reese | EVP & Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 12,407 | 66,653 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 231.89 per share. | 05 May 2023 | 594 | 54,114 (0%) | 0% | 231.9 | 137,743 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 32,250 | 32,250 | - | - | Nqso (Right to Buy) | |
| Amgen | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 3,814 | 55,527 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.97 per share. | 02 May 2023 | 819 | 54,708 (0%) | 0% | 236.0 | 193,259 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.74 per share. | 30 Apr 2023 | 666 | 51,713 (0%) | 0% | 239.7 | 159,667 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 234.57 per share. | 17 Mar 2023 | 3,978 | 52,379 (0%) | 0% | 234.6 | 933,119 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 7,947 | 56,167 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 272.06 per share. | 02 Nov 2022 | 2,440 | 48,136 (0%) | 0% | 272.1 | 663,826 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 236.10 per share. | 05 May 2022 | 575 | 50,307 (0%) | 0% | 236.1 | 135,758 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 31,817 | 31,817 | - | - | Nqso (Right to Buy) | |
| Amgen | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 3,897 | 51,652 (0%) | 0% | 0 | Common Stock | |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 230.92 per share. | 02 May 2022 | 770 | 50,882 (0%) | 0% | 230.9 | 177,808 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 249.87 per share. | 27 Apr 2022 | 184 | 47,755 (0%) | 0% | 249.9 | 45,976 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.86 per share. | 18 Mar 2022 | 4,995 | 47,939 (0%) | 0% | 235.9 | 1,178,121 | Common Stock |
| Amgen | David M. Reese | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 9,989 | 52,714 (0%) | 0% | 0 | Common Stock |